DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets has announced the addition of Espicom Business Intelligence’s New Drug Futures: Respiratory Chapter to their offering.
This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the respiratory sector. The report includes unique sales forecasts by major product.
The Respiratory market is the fourth largest therapeutic category by sales and generated nearly US$32.4 billion (+8% YoY) in 2005. Sales grew steadily in the US, which accounted for around 54% of global respiratory sales, driven by growth in Advair, GlaxoSmithKline's leading combination therapy for the treatment of asthma/COPD and Merck's Singulair for the treatment of asthma and allergic rhinitis. Sales in Europe are now growing steadily; around 5% following the uptake of new treatments such as Symbicort (AstraZeneca) and Alvesco (Altana/sanofi-aventis) which have yet to be approved in the US markets.
Over 50% of respiratory drug sales were spent on asthma and chronic obstructive pulmonary disease (COPD), the remainder is spent on other respiratory diseases such as allergic rhinitis, coughs and colds, cystic fibrosis and pneumonia. The author estimates that the asthma market was worth US$13.5 billion in 2005 and dominated by the sale of inhaled corticosteroids. The author forecasts that the current market for COPD drug therapy is worth nearly US$4.4 billion per annum and it is predicted to increase to nearly US$7 billion by 2010.
Asthma affects over 100 million people worldwide. Approximately 5%-10% of adults and 10%-15% of children suffer from asthma globally and it continues to grow at around 5%-6% per annum. Over 18 million Americans have asthma, but only around 60% of US sufferers are treated. US asthma prevalence rates have risen by almost 50% in the ten years ending 1994 and are expected to increase by 20%-50% every ten years.
COPD is the fastest-growing cause of death amongst the world's most advanced economies and is responsible for over 2.7 million deaths worldwide. It is estimated that there are up to 20 million sufferers in Japan (the highest cigarette consumption per capita of the world) and 7-10 million and 8-12 million in the US and Europe, respectively. Unfortunately, only around 40% of US COPD sufferers are adequately treated and, by 2025, the World Health Organisation estimates it will be the third leading cause of death in the world.
Answering key business questions
-Symbicort provides combination therapy for COPD and asthma in a single dose inhaler – what must AstraZeneca do to achieve sales estimated to be over US$3 billion in a market packed with competitors?
-GSK's anti-interleukin-5 humanised MAb is indicated for severe asthma, but does it offer potential in the long-term treatment of the disease?
-Sales of the Altana/sanofi-aventis drug Alvesco could reach US$892 million in 2012, but only if it can get approval for other indications and combination therapy. What is the development timeline for this product?